Publications and Posters
Presentations
Discover our newest publications and posters on cutting-edge targeted drugs for human disease
News sorted by year
2025
ARTS-023: A Potent and Selective CDK4 Inhibitor Demonstrating Anti-Tumor Activity in Preclinical ER+ Breast Cancer Models
ALRN-0192519 is a potent and selective EGFR L858R mutant allosteric inhibitor that demonstrates anti-cancer activity in preclinical models as monotherapy or in combination with osimertinib
2024
April 2024
A High-Throughput Phenotypic Screen to Identify Small Molecule Inhibitors of Werner Helicase
2023
October 2023
ARTS-021-1001: Phase I/II study of ARTS-021, a potent, oral administrated, selective CDK2 inhibitor, in advanced or metastatic solid tumors
The anti-tumor activity of CDK2 inhibition alone or in combination with other anti-cancer agents in human cancers.
CDK2 inhibition demonstrates synthetic lethality in SCLC through apoptotic induction
September 2023
ARTS-021: first patient treated
August 2023
ARTS-011: first healthy volunteer dosed
2022
May 2022
Characterization of ARTS-011, a Potent and Selective TYK2 Inhibitor for the Treatment of Inflammatory Disease
April 2022
ARTS-021 is a potent and selective CDK2 inhibitor that demonstrates anti-cancer activity in preclinical cancer models with CCNE1 amplification
